Sygnature Discovery has made two key appointments, Dr Allan Jordan and Ms Louisa Jordison. Ms Jordison joins the independent integrated drug discovery and pre-clinical services...
MSD has announced presentation of the full results from the pivotal Phase 3 KEYNOTE-426 trial investigating KEYTRUDA, MSD’s anti-PD-1 therapy, in combination with Inlyta...
This website uses cookies to improve your experience. By continuing to use this site we will assume you are ok with this. Read MoreAccept